The Sea Turtles: China’s Top Pharma Talent Comes Home
The meteoric growth of the pharmaceutical industry in China in recent years has seen a host of top Chinese talent return home from studying and working overseas to establish their…
Founded in 1988, the China Pharmaceutical Innovation and Research Development Association (PhIRDA) is registered as a non-profit organization by the Ministry of Civil Affairs of China at the first national level. PhIRDA will exert great effort on “academia-industry collaboration”, which centres on the principle of “innovation, industrialization, internationalization” and persists in innovation to achieve unmet clinical requirements.
Currently, PhIRDA has 142 members, which mainly consist of five major categories: First, start-up and R&D enterprises focusing on innovation of pharmaceutical products; Second, domestic first-class universities, colleges and research institutions conducting pharmaceutical research and development; Third clinical institutions featuring high skills in applicable research on new drugs, especially those that undertake “major new drug innovation” technological platform for good clinical practice; Fourth, investment institutions committing to pharmaceutical innovation; Fifth, national pharmaceutical enterprises excelling at innovation; Moreover, PhIRDA has established a Drug R&D Specialty Committee, Clinical Research Specialty Committee, Medicinal Policy Specialty Committee and Pharmaceutical Innovation Investment Specialty Committee, in order to promote innovation as the goal of organizational structure.
PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to continuously broaden channels of international collaboration.
Contact
Address: Room 601, CTYS Plaza, No. 5 Dongzhimen South Street, Dongcheng District, Beijing, P.R. CHINA
Tel: +86 10-58156353
Email: luxt@phirda.com, ruanxx@phirda.com
The meteoric growth of the pharmaceutical industry in China in recent years has seen a host of top Chinese talent return home from studying and working overseas to establish their…
Jin Wang, Partner and Co-leader of the McKinsey China Healthcare Practice, shares the wide-ranging scope of her focus on ‘Big Healthcare’ involving work with healthcare service providers and payers, and pharmaceutical…
China’s healthcare system, which impacts 1.4 billion people, is facing serious capacity issues at all stages of the value chain. Against this backdrop, the country is looking at making wholesale…
Given the undeniably challenging and dynamic China market, most industry stakeholders would agree that the paramount factor behind the success of multinationals’ China affiliates is talent – not only at…
2019 saw Boehringer Ingelheim (BI) veteran Felix Gutsche take up his first country manager role – of a top-three affiliate, no less – after blazing a rather unorthodox path. From…
Valtero Canepa, general manager for China of Italian family-owned diagnostic imaging specialist Bracco, outlines the importance of China for the firm, the complexities of operating an international joint venture, and…
White Wang, president of Allergan China, shares the uniqueness of Allergan as a diversified company covering traditional pharmaceuticals and medical aesthetics; the milestones of his first year, with major projects…
Li Qing of Illumina China discusses his recent move to the company, the strategic significance of the China market to Illumina global, and the competitive landscape for next generation sequencing…
Japanese ophthalmology specialist Santen first established a China affiliate in 2005 and has grown very successfully in the past 14 years. GM of Santen Pharmaceutical (China) Co., Ltd. (hereafter, Santen…
China’s pharma market is growing at an unprecedented pace and has become a key element of virtually all pharma multinationals’ international strategies. However, with a spate of regulatory reforms being…
Kirsch Pharma is a raw materials provider to the pharmaceutical, nutritional, biotechnology, veterinary and cosmetic industries. The business in China was established in 1997, importing high-quality raw materials from Germany.…
Global medical aesthetics market leader Allergan is investing heavily in the Chinese city of Chengdu and has launched a number of initiatives there, including a global consumer experience centre, an…
See our Cookie Privacy Policy Here
